AGING?F***THAT!
18 OCTOBER 2026 ยท LEE C. STONEHOUSE
3D graphic contrasting a scattergun spray of multivitamin capsules with one targeted capsule aligned to a biomarker readout

A multivitamin is a scattergun with no target. A measured intervention starts with a signal worth acting on.

The Multivitamin Myth: Why the Only Honest Reason to Swallow a Pill Is a Blood Test First

A daily multivitamin can feel like sensible insurance: one small habit, a broad promise, and no need to know what the body actually needs.

But when researchers examined more than 20 years of data from 390,124 generally healthy adults, daily multivitamin use was not associated with a lower risk of death. That does not mean every supplement is useless. It means the case for a broad-spectrum pill is not the same as the case for correcting a deficiency that has been measured.

That distinction matters for healthspan. Guessing is not a system. Measure first. Intervene only where there is a reason. Retest to check whether the intervention worked.

THE VERDICT: INSURANCE IS OUT

What the large multivitamin study actually found

Loftfield and colleagues analysed data from three prospective US cohorts, including the NIH-AARP Diet and Health Study. The 390,124 participants were generally healthy adults, followed for more than 20 years.

The researchers found that daily multivitamin use was not associated with a lower risk of death from any cause. That included deaths from cancer, cardiovascular disease and cerebrovascular disease. The authors found no evidence that multivitamins improve longevity in healthy adults. Read the study in JAMA Network Open.

This was an observational study, not a randomized trial. It can identify an association, but it cannot prove that taking a multivitamin causes a particular outcome. Nor does it test whether a person with a confirmed nutrient deficiency might benefit from an appropriate supplement.

The fair conclusion is narrower, and more useful: for generally healthy adults, the findings do not support taking a daily multivitamin as a proven way to live longer.

That puts the insurance story under pressure. A pill containing many nutrients is not automatically a meaningful intervention simply because it is convenient.

THE USPSTF VERDICT: NOT ALL PILLS GET THE SAME ANSWER

The US Preventive Services Task Force (USPSTF) considered supplements for the prevention of cardiovascular disease and cancer in community-dwelling adults. In its 2022 recommendation, it advised against using beta-carotene or vitamin E supplements for those preventive purposes. The task force judged there to be moderate certainty of no net benefit or harm.

For multivitamins, and for single- or paired-nutrient supplements other than beta-carotene and vitamin E, the USPSTF issued an “I statement.” That means the available evidence was insufficient to determine whether the benefits outweigh the harms for preventing cardiovascular disease or cancer. It is not a blanket instruction that every supplement is harmful, and it is not proof that every supplement is beneficial. Read the USPSTF recommendation.

3D evidence graphic showing beta-carotene and vitamin E supplements beside a clear caution verdict

The USPSTF recommends against beta-carotene and vitamin E supplements for cardiovascular disease or cancer prevention.

The practical lesson is to stop treating “supplements” as one category. The evidence and the purpose matter. A broad promise to prevent disease is different from correcting a specific, measured shortfall.

THE NUANCE: A TESTED DEFICIENCY IS A DIFFERENT CASE

A supplement may have a clear role when testing identifies a deficiency and a qualified health professional determines that correction is appropriate. That is not multivitamin insurance. It is a targeted response to a measured finding.

The distinction is simple:

Scattergun: take a broad blend without knowing whether its contents address a need.
Targeted correction: identify a low result, choose an appropriate intervention with professional guidance, and set a plan to reassess.

Dose and follow-up matter. A test provides a starting point, not a reason to self-diagnose or self-treat. The response should be reviewed, and the relevant result should be checked again when appropriate. If the expected change does not occur, the next step is to reassess, not to add more pills by guesswork.

Vitamin D is a useful UK example of why context matters. UK survey data indicate that roughly 23% of adults aged 19–64 and 39% of adults aged 65 and over take at least one dietary supplement. Low vitamin D affects roughly 12–23% of adults, depending on age and season. UK guidance supports supplementation for people at risk. These facts do not establish that everyone should take vitamin D to extend lifespan, nor do they make supplementation a substitute for individual assessment.

The honest model is not “vitamin D for everyone.” It is to understand the person’s circumstances, use testing where clinically appropriate, and follow qualified guidance on whether supplementation is needed. See UK vitamin D guidance.

3D vitamin D molecule landing beside a highlighted biomarker line on a laboratory report

A targeted supplement approach starts with a relevant finding and includes a plan to verify the response.

That is the difference between swallowing a pill because it seems prudent and using one as part of a measured correction. The pill is not the strategy. The decision-making process is.

THE COSMOS LESSON: READ THE WHOLE RESULT

Supplement science can produce a headline that sounds definitive while the underlying finding is more specific.

In the COSMOS randomized trial, researchers studied cocoa extract providing 500 mg of flavanols per day. Over a median follow-up of 3.6 years, the primary composite cardiovascular endpoint was not significantly reduced: the hazard ratio was 0.90, with a 95% confidence interval of 0.78–1.02.

The study also reported a 27% reduction in cardiovascular death, a secondary finding (hazard ratio 0.73, 95% confidence interval 0.54–0.98). That result is intriguing. It deserves attention. But one secondary finding in one trial is a hypothesis to investigate, not a prescription. Read the COSMOS trial in the American Journal of Clinical Nutrition.

3D cocoa flavanol molecule beside a probability chart showing an inconclusive primary result and a distinct secondary signal

COSMOS produced an interesting secondary signal, while its primary cardiovascular endpoint was not significant.

That is how to read supplement research honestly: check the primary outcome, distinguish it from secondary findings, and resist turning a promising result into a universal recommendation.

THE OPERATING SYSTEM: TEST, TARGET, RETEST

A useful healthspan approach has a sequence. It does not begin with a shopping basket.

1. Test. Establish relevant baseline information through appropriate assessments and independent lab biomarker tracking.

2. Target. Choose an intervention that addresses a measured need. If no relevant need has been identified, a multivitamin should not be treated as automatic insurance.

3. Retest. Check whether the result changed. If it did not, review the plan with an appropriate professional rather than adding supplements blindly.

This is the logic behind Lee C. Stonehouse’s data-driven approach: biomarker tracking comes before an intervention, and follow-up helps determine whether the chosen action produced a measurable response. The biological age test versus a calculator article explains what biological-age assessment actually measures; it is not a diagnosis or a guarantee of future health.

Lee became a personal trainer at 21 in California after competing as a bodybuilder. He wrote The Healthspan Extension Manual and built its 10-Tenet operating system. That framework connects attitude, nutrition, exercise, sleep, stress control, hormones and genetics, self-care, love and community, consistency, and cosmetic presentation.

Lee’s own biological age was assessed at 47 against a chronological age of 63. That result is a personal example, not a promise that another person will receive the same assessment or outcome. Its relevance here is the method: measure, act deliberately, and assess again.

Healthspan is about more than a single number or a supplement routine. The distinction between healthspan vs lifespan is a useful reminder: the goal is to preserve capability, not simply collect years. For a broader foundation, explore healthspan after 40.

A PRACTICAL CLOSE FOR BRIGHTON & HOVE

A longevity clinic should not sell certainty in a capsule. It should help people ask better questions, understand what their measurements can and cannot show, and follow a considered process. For people within a 10 mile radius of Brighton & Hove city centre, the same principle applies: start with evidence, not a supplement label.

This article is educational, not medical advice. Supplement decisions, testing and treatment should be discussed with an appropriately qualified healthcare professional.

For a conversation about Lee’s measured healthspan approach, contact him exclusively through WhatsApp by voice note, text or voice call.

Ready to replace guesswork with a measured plan? Contact Lee on WhatsApp.

FREQUENTLY ASKED QUESTIONS

Do multivitamins help healthy adults live longer?

A large observational study of generally healthy US adults found that daily multivitamin use was not associated with lower mortality from any cause, cancer, cardiovascular disease or cerebrovascular disease. The study does not prove that multivitamins cause harm, but it provides no evidence that taking one improves longevity in healthy adults.

Should everyone over 40 take a multivitamin?

The evidence does not support treating a multivitamin as automatic insurance for everyone over 40. A broad-spectrum product may not address an individual need. A more considered approach is to discuss relevant testing and health circumstances with a qualified professional before deciding whether any supplement is appropriate.

Is vitamin D an exception to the multivitamin evidence?

Vitamin D has a distinct UK public-health context: low vitamin D is reported among adults, and UK guidance supports supplementation for people at risk. That does not mean everyone should take it for longevity. Individual circumstances and professional guidance matter, particularly when deficiency or treatment is being considered.

What does a blood-test-first supplement approach involve?

It means using appropriate assessment to identify a relevant low result, discussing a suitable response with a qualified professional, and planning a follow-up assessment where appropriate. The aim is to address a measured need and verify the response, not to take several supplements speculatively or keep increasing a dose without review.

DEEP DIVE: SOURCES